Skip to main content
PMC home page
The American Journal of Pathology logoLink to The American Journal of Pathology
. 1997 Jan;150(1):81–89.

Gain of chromosome 17 is the most frequent abnormality detected in neuroblastoma by comparative genomic hybridization.

D Plantaz 1, G Mohapatra 1, K K Matthay 1, M Pellarin 1, R C Seeger 1, B G Feuerstein 1
PMCID: PMC1858505  PMID: 9006325

Abstract

Neuroblastoma behavior is variable and outcome partially depends on genetic factors. However, tumors that lack high-risk factors such as MYCN amplification or 1p deletion may progress, possibly due to other genetic aberrations. Comparative genomic hybridization summarizes DNA copy number abnormalities in a tumor by mapping them to their positions on normal metaphase chromosomes. We analyzed 29 tumors from nearly equal proportions of children with stage I, II, III, IV, and IV-S disease by comparative genomic hybridization. We found two classes of copy number abnormalities: whole chromosome and partial chromosome. Whole chromosome losses were frequent at 11, 14, and X. The most frequent partial chromosome losses were on 1p and 11q. Gains were most frequent on chromosome 17 (72% of cases). The two patterns of gain for this chromosome were whole 17 gain and 17q gain, with 17q21-qter as a minimal common region of gain. Other common gains were on chromosomes 7, 6, and 18. High level amplifications were detected at 2p23-25 (MYCN region), at 4q33-35, and at 6p11-22. Chromosome 17q gains were associated with 1p and/or 11q deletions and advanced stage. The high frequency of chromosome 17 gain and its association with bad prognostic factors suggest an important role for this chromosome in the development of neuroblastoma.

Full text

PDF
82

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bader S. A., Fasching C., Brodeur G. M., Stanbridge E. J. Dissociation of suppression of tumorigenicity and differentiation in vitro effected by transfer of single human chromosomes into human neuroblastoma cells. Cell Growth Differ. 1991 May;2(5):245–255. [PubMed] [Google Scholar]
  2. Bourhis J., De Vathaire F., Wilson G. D., Hartmann O., Terrier-Lacombe M. J., Boccon-Gibod L., McNally N. J., Lemerle J., Riou G., Bénard J. Combined analysis of DNA ploidy index and N-myc genomic content in neuroblastoma. Cancer Res. 1991 Jan 1;51(1):33–36. [PubMed] [Google Scholar]
  3. Brodeur G. M., Azar C., Brother M., Hiemstra J., Kaufman B., Marshall H., Moley J., Nakagawara A., Saylors R., Scavarda N. Neuroblastoma. Effect of genetic factors on prognosis and treatment. Cancer. 1992 Sep 15;70(6 Suppl):1685–1694. doi: 10.1002/1097-0142(19920915)70:4+<1685::aid-cncr2820701607>3.0.co;2-h. [DOI] [PubMed] [Google Scholar]
  4. Brodeur G. M., Green A. A., Hayes F. A., Williams K. J., Williams D. L., Tsiatis A. A. Cytogenetic features of human neuroblastomas and cell lines. Cancer Res. 1981 Nov;41(11 Pt 1):4678–4686. [PubMed] [Google Scholar]
  5. Brodeur G. M., Seeger R. C., Schwab M., Varmus H. E., Bishop J. M. Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. Science. 1984 Jun 8;224(4653):1121–1124. doi: 10.1126/science.6719137. [DOI] [PubMed] [Google Scholar]
  6. Caron H., Peter M., van Sluis P., Speleman F., de Kraker J., Laureys G., Michon J., Brugières L., Voûte P. A., Westerveld A. Evidence for two tumour suppressor loci on chromosomal bands 1p35-36 involved in neuroblastoma: one probably imprinted, another associated with N-myc amplification. Hum Mol Genet. 1995 Apr;4(4):535–539. doi: 10.1093/hmg/4.4.535. [DOI] [PubMed] [Google Scholar]
  7. Caron H., van Sluis P., de Kraker J., Bökkerink J., Egeler M., Laureys G., Slater R., Westerveld A., Voûte P. A., Versteeg R. Allelic loss of chromosome 1p as a predictor of unfavorable outcome in patients with neuroblastoma. N Engl J Med. 1996 Jan 25;334(4):225–230. doi: 10.1056/NEJM199601253340404. [DOI] [PubMed] [Google Scholar]
  8. Christiansen H., Lampert F. Tumour karyotype discriminates between good and bad prognostic outcome in neuroblastoma. Br J Cancer. 1988 Jan;57(1):121–126. doi: 10.1038/bjc.1988.24. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Fong C. T., White P. S., Peterson K., Sapienza C., Cavenee W. K., Kern S. E., Vogelstein B., Cantor A. B., Look A. T., Brodeur G. M. Loss of heterozygosity for chromosomes 1 or 14 defines subsets of advanced neuroblastomas. Cancer Res. 1992 Apr 1;52(7):1780–1785. [PubMed] [Google Scholar]
  10. Gilbert F., Feder M., Balaban G., Brangman D., Lurie D. K., Podolsky R., Rinaldt V., Vinikoor N., Weisband J. Human neuroblastomas and abnormalities of chromosomes 1 and 17. Cancer Res. 1984 Nov;44(11):5444–5449. [PubMed] [Google Scholar]
  11. Hailat N., Keim D. R., Melhem R. F., Zhu X. X., Eckerskorn C., Brodeur G. M., Reynolds C. P., Seeger R. C., Lottspeich F., Strahler J. R. High levels of p19/nm23 protein in neuroblastoma are associated with advanced stage disease and with N-myc gene amplification. J Clin Invest. 1991 Jul;88(1):341–345. doi: 10.1172/JCI115299. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Hayashi Y., Kanda N., Inaba T., Hanada R., Nagahara N., Muchi H., Yamamoto K. Cytogenetic findings and prognosis in neuroblastoma with emphasis on marker chromosome 1. Cancer. 1989 Jan 1;63(1):126–132. doi: 10.1002/1097-0142(19890101)63:1<126::aid-cncr2820630120>3.0.co;2-z. [DOI] [PubMed] [Google Scholar]
  13. Kallioniemi A., Kallioniemi O. P., Sudar D., Rutovitz D., Gray J. W., Waldman F., Pinkel D. Comparative genomic hybridization for molecular cytogenetic analysis of solid tumors. Science. 1992 Oct 30;258(5083):818–821. doi: 10.1126/science.1359641. [DOI] [PubMed] [Google Scholar]
  14. Kallioniemi O. P., Kallioniemi A., Piper J., Isola J., Waldman F. M., Gray J. W., Pinkel D. Optimizing comparative genomic hybridization for analysis of DNA sequence copy number changes in solid tumors. Genes Chromosomes Cancer. 1994 Aug;10(4):231–243. doi: 10.1002/gcc.2870100403. [DOI] [PubMed] [Google Scholar]
  15. Laureys G., Speleman F., Opdenakker G., Benoit Y., Leroy J. Constitutional translocation t(1;17)(p36;q12-21) in a patient with neuroblastoma. Genes Chromosomes Cancer. 1990 Sep;2(3):252–254. doi: 10.1002/gcc.2870020315. [DOI] [PubMed] [Google Scholar]
  16. Leone A., Seeger R. C., Hong C. M., Hu Y. Y., Arboleda M. J., Brodeur G. M., Stram D., Slamon D. J., Steeg P. S. Evidence for nm23 RNA overexpression, DNA amplification and mutation in aggressive childhood neuroblastomas. Oncogene. 1993 Apr;8(4):855–865. [PubMed] [Google Scholar]
  17. Look A. T., Hayes F. A., Shuster J. J., Douglass E. C., Castleberry R. P., Bowman L. C., Smith E. I., Brodeur G. M. Clinical relevance of tumor cell ploidy and N-myc gene amplification in childhood neuroblastoma: a Pediatric Oncology Group study. J Clin Oncol. 1991 Apr;9(4):581–591. doi: 10.1200/JCO.1991.9.4.581. [DOI] [PubMed] [Google Scholar]
  18. Maris J. M., White P. S., Beltinger C. P., Sulman E. P., Castleberry R. P., Shuster J. J., Look A. T., Brodeur G. M. Significance of chromosome 1p loss of heterozygosity in neuroblastoma. Cancer Res. 1995 Oct 15;55(20):4664–4669. [PubMed] [Google Scholar]
  19. McDonald J. D., Daneshvar L., Willert J. R., Matsumura K., Waldman F., Cogen P. H. Physical mapping of chromosome 17p13.3 in the region of a putative tumor suppressor gene important in medulloblastoma. Genomics. 1994 Sep 1;23(1):229–232. doi: 10.1006/geno.1994.1481. [DOI] [PubMed] [Google Scholar]
  20. Mertens F., Johansson B., Mitelman F. Isochromosomes in neoplasia. Genes Chromosomes Cancer. 1994 Aug;10(4):221–230. doi: 10.1002/gcc.2870100402. [DOI] [PubMed] [Google Scholar]
  21. Mohapatra G., Kim D. H., Feuerstein B. G. Detection of multiple gains and losses of genetic material in ten glioma cell lines by comparative genomic hybridization. Genes Chromosomes Cancer. 1995 Jun;13(2):86–93. doi: 10.1002/gcc.2870130203. [DOI] [PubMed] [Google Scholar]
  22. Piper J., Rutovitz D., Sudar D., Kallioniemi A., Kallioniemi O. P., Waldman F. M., Gray J. W., Pinkel D. Computer image analysis of comparative genomic hybridization. Cytometry. 1995 Jan 1;19(1):10–26. doi: 10.1002/cyto.990190104. [DOI] [PubMed] [Google Scholar]
  23. Savelyeva L., Corvi R., Schwab M. Translocation involving 1p and 17q is a recurrent genetic alteration of human neuroblastoma cells. Am J Hum Genet. 1994 Aug;55(2):334–340. [PMC free article] [PubMed] [Google Scholar]
  24. Schleiermacher G., Peter M., Michon J., Hugot J. P., Vielh P., Zucker J. M., Magdelénat H., Thomas G., Delattre O. Two distinct deleted regions on the short arm of chromosome 1 in neuroblastoma. Genes Chromosomes Cancer. 1994 Aug;10(4):275–281. doi: 10.1002/gcc.2870100409. [DOI] [PubMed] [Google Scholar]
  25. Schwab M., Alitalo K., Klempnauer K. H., Varmus H. E., Bishop J. M., Gilbert F., Brodeur G., Goldstein M., Trent J. Amplified DNA with limited homology to myc cellular oncogene is shared by human neuroblastoma cell lines and a neuroblastoma tumour. Nature. 1983 Sep 15;305(5931):245–248. doi: 10.1038/305245a0. [DOI] [PubMed] [Google Scholar]
  26. Seeger R. C., Brodeur G. M., Sather H., Dalton A., Siegel S. E., Wong K. Y., Hammond D. Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas. N Engl J Med. 1985 Oct 31;313(18):1111–1116. doi: 10.1056/NEJM198510313131802. [DOI] [PubMed] [Google Scholar]
  27. Shapiro D. N., Valentine M. B., Rowe S. T., Sinclair A. E., Sublett J. E., Roberts W. M., Look A. T. Detection of N-myc gene amplification by fluorescence in situ hybridization. Diagnostic utility for neuroblastoma. Am J Pathol. 1993 May;142(5):1339–1346. [PMC free article] [PubMed] [Google Scholar]
  28. Srivatsan E. S., Ying K. L., Seeger R. C. Deletion of chromosome 11 and of 14q sequences in neuroblastoma. Genes Chromosomes Cancer. 1993 May;7(1):32–37. doi: 10.1002/gcc.2870070106. [DOI] [PubMed] [Google Scholar]
  29. Takayama H., Suzuki T., Mugishima H., Fujisawa T., Ookuni M., Schwab M., Gehring M., Nakamura Y., Sugimura T., Terada M. Deletion mapping of chromosomes 14q and 1p in human neuroblastoma. Oncogene. 1992 Jun;7(6):1185–1189. [PubMed] [Google Scholar]
  30. Takeda O., Homma C., Maseki N., Sakurai M., Kanda N., Schwab M., Nakamura Y., Kaneko Y. There may be two tumor suppressor genes on chromosome arm 1p closely associated with biologically distinct subtypes of neuroblastoma. Genes Chromosomes Cancer. 1994 May;10(1):30–39. doi: 10.1002/gcc.2870100106. [DOI] [PubMed] [Google Scholar]
  31. Van Roy N., Laureys G., Cheng N. C., Willem P., Opdenakker G., Versteeg R., Speleman F. 1;17 translocations and other chromosome 17 rearrangements in human primary neuroblastoma tumors and cell lines. Genes Chromosomes Cancer. 1994 Jun;10(2):103–114. doi: 10.1002/gcc.2870100205. [DOI] [PubMed] [Google Scholar]
  32. Vogan K., Bernstein M., Leclerc J. M., Brisson L., Brossard J., Brodeur G. M., Pelletier J., Gros P. Absence of p53 gene mutations in primary neuroblastomas. Cancer Res. 1993 Nov 1;53(21):5269–5273. [PubMed] [Google Scholar]

Articles from The American Journal of Pathology are provided here courtesy of American Society for Investigative Pathology

RESOURCES